Seres Therapeutics, INC Form 4 insider transactions

Kurt Graves, a Director at Seres Therapeutics, Inc., acquired stock options for 6,500 shares of common stock.

Richard N. Kender, Director and Officer at Seres Therapeutics, acquired 50,000 stock options with an exercise price of $9.13.

Matthew R. Henn, President and Chief Scientific Officer of Seres Therapeutics, Inc., was granted 25,000 stock options with an exercise price of $9.13.

Marella Thorell, EVP and Chief Financial Officer of Seres Therapeutics, Inc., acquired 7,500 stock options.

Claire Fraser, a Director at Seres Therapeutics, Inc., reported the acquisition of stock options.

Willard H. Dere, a Director at Seres Therapeutics, Inc., acquired stock options for 6,500 shares of common stock.

Director Dennis A. Ausiello of Seres Therapeutics, Inc. acquired 6,500 stock options on July 8, 2026, as detailed in a Form 4 filing.

Seres Therapeutics Director Eric D. Shaff acquired stock options for 6,500 shares of common stock on July 8, 2026.

Robert L. Rosiello, a Director at Seres Therapeutics, Inc., acquired stock options for 6,500 shares.

Director Stephen Berenson of Seres Therapeutics, Inc. acquired stock options for 6,500 shares.

Thomas DesRosier, EVP and Chief Legal Officer of Seres Therapeutics, acquired 7,500 stock options on July 8, 2026.

Director Stephen Berenson of Seres Therapeutics, Inc. acquired stock options on July 1, 2026, as detailed in a Form 4 filing.

Robert L. Rosiello, a Director at Seres Therapeutics, Inc., acquired stock options on July 1, 2026, with an exercise price of $7.94.

Seres Therapeutics Director Dennis A. Ausiello was granted stock options for 7,508 shares of common stock.

Thomas DesRosier, EVP and Chief Legal Officer at Seres Therapeutics, Inc., reported transactions involving the acquisition and sale of common stock, including those related to restricted stock units.

Director Eric D. Shaff of Seres Therapeutics, Inc. (MCRB) reported transactions involving common stock and restricted stock units.

Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, Inc., engaged in transactions involving the acquisition and sale of company common stock, primarily related to tax obligations from vested restricted stock units.

Kelly Brady, Chief Operating Officer at Seres Therapeutics, acquired restricted stock units and sold shares to cover taxes.

Seres Therapeutics' Interim CEO, Richard N. Kender, was granted 150,000 stock options with an exercise price of $9.13, vesting over 36 months.

Seres Therapeutics, Inc. granted 75,000 stock options to President and Chief Scientific Officer Matthew R. Henn with an exercise price of $9.13.

Seres Therapeutics' EVP and Chief Financial Officer, Marella Thorell, acquired 22,500 stock options with an exercise price of $9.13, vesting over several years.

Seres Therapeutics' EVP and Chief Legal Officer, Thomas DesRosier, was granted 22,500 stock options with an exercise price of $9.13.

Seres Therapeutics EVP Teresa L. Young vested 4,228 RSUs and sold 1,042 shares at $17.30 under a Rule 10b5-1 plan to cover taxes, ending with 8,401 shares owned directly.

Seres Therapeutics director Eric D. Shaff net-sold 217 shares at $17.30 under a pre-set 10b5-1 plan following RSU vesting and now directly owns 11,113 shares.

Thomas J. DesRosier acquired 244 shares via RSU vesting and sold 76 shares at $17.3 to cover taxes, ending with 7,623 directly owned shares and 1,665 RSUs outstanding.

Chief Scientific Officer Matthew R. Henn converted 4,236 RSUs and sold 1,257 shares at $17.3 under a pre-set Rule 10b5-1 plan to cover taxes, retaining 7,527 shares and 1,582 unvested RSUs.

Teresa L. Young, EVP, Chief Commercial & Strategy Officer at Seres Therapeutics, Inc., was granted 3,998 restricted stock units, vesting on November 15, 2025.

Seres Therapeutics, Inc. granted 3,998 Restricted Stock Units to Chief Scientific Officer and EVP Matthew R. Henn, aligning executive incentives with shareholder value.

Seres Therapeutics' EVP, Chief Commercial & Strategy Officer, Teresa L. Young, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Seres Therapeutics Director Eric D. Shaff reported the acquisition of common stock through RSU vesting and subsequent sale of shares to cover tax obligations under a pre-arranged 10b5-1 plan.